{
    "nctId": "NCT00717015",
    "briefTitle": "Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer",
    "officialTitle": "Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": "N/A",
    "primaryOutcomeMeasure": "To determine the steady state pharmacokinetics of tamoxifen and its metabolites",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent.\n* At least 18 years of age.\n* On tamoxifen for at least 3 months for adjuvant therapy.\n* On a stable diet for past 1 week before blood sampling.\n* Compliant with tamoxifen medication.\n* Completed adjuvant chemotherapy and/or adjuvant radiation therapy.\n\nExclusion Criteria:\n\n\u2022 Patients should not be on the list of medications for the last 1 week before accrual to the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}